Cholesterol-lowering drugs reduce risk of stroke, heart attack

May 02, 2007

People whose cholesterol improved after one month on cholesterol-lowering drugs called statins reduced their risk of stroke and heart attack, according to research that will be presented at the American Academy of Neurology’s 59th Annual Meeting in Boston.

The study enrolled 4,731 people within one to six months of having a stroke or transient ischemic attack, or mini-stroke, and with no history of heart disease. Half of the participants received the cholesterol-lowering drug atorvastatin and half received a placebo. The participants were then followed for an average of four and a half years.

For each 10-percent decrease in LDL, or low-density lipoprotein “bad” cholesterol, the risk of stroke was reduced by four percent and the risk of heart attack was reduced by seven percent. The average decrease in LDL cholesterol after one month on atorvastatin was 53 percent.

“These findings reinforce the importance of controlling cholesterol,” said study author Pierre Amarenco, MD, of Denis Diderot University in Paris, France, and Fellow member of the American Academy of Neurology. “It’s encouraging to see that reducing cholesterol so quickly can have positive long-term effects.”

People with higher levels of HDL, or high-density lipoprotein “good” cholesterol, at the beginning of the study and after one month had a lower risk of stroke.

Source: American Academy of Neurology

Explore further: FDA OKs Cubist antibiotic for serious infections

add to favorites email to friend print save as pdf

Related Stories

A medical lab for the home

Nov 04, 2014

Fraunhofer FIT demonstrates a mobile wireless system that monitors the health of elderly people in their own homes, using miniature sensors. Besides non-invasive sensors this platform integrates technology ...

Golden retriever study sniffs for cancer clues

Sep 11, 2014

(HealthDay)—Michael Court is a scientist and a dog lover, so he jumped at the chance to enroll his golden retriever in a nationwide study aimed at fighting cancer and other ills in canines.

Recommended for you

FDA OKs Cubist antibiotic for serious infections

Dec 20, 2014

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

Dec 18, 2014

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.